Skip to main content

Eptifibatide Injection

Last Updated: November 29, 2022
Status: Current

Products Affected - Description
    • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
    • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
    • Eptifibatide injection, Eugia US, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
    • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
    • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10
    • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
    • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80
Reason for the Shortage
    • Accord has temporarily discontinued eptifibatide injection.
    • Akorn is not currently marketing eptifibatide.
    • Amneal did not provide a reason for the shortage.
    • Baxter has eptifibatide injection available.
    • Eugia did not provide a reason for the shortage.
    • Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
    • Viatris did not provide a reason for the shortage.
    • Sagent states the shortage is due to manufacturing delay.
    • Slate Run has eptifibatide injection available.
Available Products
    • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
    • Eptifibatide injection, Eugia US, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
    • Eptifibatide injection, Eugia US, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10

Estimated Resupply Dates

    • Amneal has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on long-term back order and the company cannot estimate a release date.
    • Eugia has eptifibatide 2 mg/mL in 100 mL vials available with a short expiry of August 2023.
    • Sagent has eptifibatide 2 mg/mL in 10 mL vials on back order and the company cannot estimate a release date. The 0.75 mg/mL in 100 mL vials are available in limited allocation.
    • Slate Run has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on allocation.

Updated

Updated November 29, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.